Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic
lupus erythematosus in male and female adults. Patients who qualify will be randomized to
either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the
initial 24 weeks of treatment and who are responding to therapy will have the option to
continue receiving BMS-931699 as part of a long-term extension (LTE). Disease activity and
safety will be assessed over the course of the study through laboratory values, various
rating scales accepted in systemic lupus erythematosus studies and patient self reporting.